FDA Considers Meeting With Firms Before Ordering Section 522 Studies
This article was originally published in The Gray Sheet
Executive Summary
FDA’s device center seems agreeable to the concept of “pre-522” study meetings, raised by industry last week as a means to make the post-market study order process more efficient.